AstraZeneca Reports BRILINTA  Monotherapy In High-bleeding Risk Patients Who Underwent Pci Had Reduced Risk Of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy In The Twilight Trial; Says Achieved Secondary Endpoint Of Non-Inferiority